A single intranasal dose of chimpanzee adenovirus-vectored vaccine protects against SARS-CoV-2 infection in rhesus macaques.
A single intranasal dose of chimpanzee adenovirus-vectored vaccine protects against SARS-CoV-2 infection in rhesus macaques.
复制标题
DOI：
10.1016/j.xcrm.2021.100230
复制
发表时间：
2021-04-20
期刊：
影响因子：
--
通讯作者：
Diamond MS
中科院分区：
文献类型：
--
作者：
Hassan AO;Feldmann F;Zhao H;Curiel DT;Okumura A;Tang-Huau TL;Case JB;Meade-White K;Callison J;Chen RE;Lovaglio J;Hanley PW;Scott DP;Fremont DH;Feldmann H;Diamond MS
要结束2019冠状病毒病（COVID-19）大流行，需要部署一种限制传播和疾病的疫苗。我们最近描述了鼻内给予的黑猩猩腺病毒载体疫苗编码融合前稳定的刺突（S）蛋白（ChAd-SARS-CoV-2-S [黑猩猩腺病毒-严重急性呼吸综合征-冠状病毒-2-S]）在表达人血管紧张素转换酶2（ACE 2）受体的小鼠上呼吸道和下呼吸道中的保护活性。在这里，我们展示了这种疫苗在非人灵长类动物中的免疫原性和保护效力。用ChAd-Control或ChAd-SARS-CoV-2-S免疫恒河猴，并在1个月后通过鼻内和支气管内途径用SARS-CoV-2进行攻击。单次鼻内剂量的ChAd-SARS-CoV-2-S诱导中和抗体和T细胞应答，并限制或预防SARS-CoV-2攻击后上呼吸道和下呼吸道的感染。由于ChAd-SARS-CoV-2-S在非人灵长类动物中具有保护作用，因此它是限制SARS-CoV-2在人类中感染和传播的有希望的候选者。ChAD-SARS-CoV-2是一种针对SARS-CoV-2的黑猩猩腺病毒载体疫苗ChAD-SARS-CoV-2-S免疫诱导NHP中的中和抗体和T细胞应答ChAD-SARS-CoV-2-S保护NHP免受呼吸道感染疫苗诱导的血清中和抗体滴度与保护哈桑et al.显示通过鼻内途径用ChAd-SARS-CoV-2-S单剂量免疫恒河猴诱导针对SARS-CoV-2的中和抗体和T细胞应答。ChAd-SARS-CoV-2-S疫苗可保护恒河猴上呼吸道和下呼吸道免受SARS-CoV-2感染。
The deployment of a vaccine that limits transmission and disease likely will be required to end the coronavirus disease 2019 (COVID-19) pandemic. We recently described the protective activity of an intranasally administered chimpanzee adenovirus-vectored vaccine encoding a pre-fusion stabilized spike (S) protein (ChAd-SARS-CoV-2-S [chimpanzee adenovirus-severe acute respiratory syndrome-coronavirus-2-S]) in the upper and lower respiratory tracts of mice expressing the human angiotensin-converting enzyme 2 (ACE2) receptor. Here, we show the immunogenicity and protective efficacy of this vaccine in non-human primates. Rhesus macaques were immunized with ChAd-Control or ChAd-SARS-CoV-2-S and challenged 1 month later by combined intranasal and intrabronchial routes with SARS-CoV-2. A single intranasal dose of ChAd-SARS-CoV-2-S induces neutralizing antibodies and T cell responses and limits or prevents infection in the upper and lower respiratory tracts after SARS-CoV-2 challenge. As ChAd-SARS-CoV-2-S confers protection in non-human primates, it is a promising candidate for limiting SARS-CoV-2 infection and transmission in humans. ChAd-SARS-CoV-2 is a chimpanzee adenoviral vectored vaccine against SARS-CoV-2 ChAD-SARS-CoV-2-S immunization induces neutralizing Abs and T cell responses in NHP ChAD-SARS-CoV-2-S protects NHPs against infection in the respiratory tract Vaccine-induced serum neutralizing antibody titers correlate with the protection Hassan et al. show that a single-dose immunization of rhesus monkeys with ChAd-SARS-CoV-2-S via an intranasal route induces neutralizing antibodies and T cell responses against SARS-CoV-2. ChAd-SARS-CoV-2-S vaccine protects rhesus monkeys against SARS-CoV-2 infection in both the upper and lower respiratory tracts.